サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：チューブレスインスリンポンプの世界市場 - 2023年～2030年
市場調査レポート
商品コード
1374847

チューブレスインスリンポンプの世界市場 - 2023年～2030年

Global Tubeless Insulin Pumps Market - 2023-2030

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
チューブレスインスリンポンプの世界市場 - 2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

チューブレスインスリンポンプは、基本的に体に直接パッチとして装着し、ワイヤレスハンドヘルドデバイスから制御することで、目立たないインスリン送達を可能にします。ポンプには画面がなく、タッチスクリーンのハンドヘルドからBluetoothを介してワイヤレスで制御されます。このポンプには、防水で閉ループのインスリンポンプに配置されたアルゴリズムが含まれており、インスリン放出プロセスのために持続グルコースモニターと直接通信します。

さらに、チューブレスインスリンポンプは、1型および2型糖尿病患者の血糖値管理に便利です。これらの小型デバイスは、特定の時間にインスリンを投与します。チューブレスインスリンポンプは、インスリンペン注射や他のインスリンデバイスよりも柔軟なオプションです。これらは永続的である必要はなく、いつでも別のインスリン管理方法に切り替えることができます。チューブレスインスリンポンプは患者にとって好都合であり、インスリン送達はワイヤレスデバイスを使用して行うことができます。

市場力学：促進要因

チューブレスインスリンポンプの進歩の増加

チューブレスポンプの進歩の増加は、予測期間にわたって市場を牽引すると予想されます。これらのポンプの進歩は、チューブレスインスリンポンプの採用を増加させると予想されます。チューブレスインスリンポンプ技術の進歩は、より小型で、より快適で、より使いやすいデバイスをもたらす可能性があります。ユーザーエクスペリエンスの向上は、患者の満足度向上につながる可能性があります。

例えば、2023年8月、ロシュ社はアキュチェック・ソロ・インスリンパッチポンプとワイヤレス・タッチスクリーン・ハンドヘルドデバイスを発売し、2歳以上の糖尿病患者を対象にFDAの承認を取得しました。このシステムにはチューブレスインスリンポンプとブルートゥース搭載のワイヤレスハンドヘルドコントローラーが含まれ、血糖モニタリングと統合し、ボーラスアドバイスを提供します。このインスリンポンプシステムはチューブレスで小型軽量。装置は取り外し可能で、糖尿病患者は必要に応じて注入部位を変更することができます。

さらに、チューブレスインスリンポンプがCGMシステムとシームレスに統合できるように設計され、より良いグルコースモニタリングと自動インスリン調整が可能になれば、糖尿病管理を大幅に強化することができます。その結果、患者の転帰が改善され、さらに先進的な機器の採用が増加します。

例えば、2023年6月20日、チューブレスインスリンポンプ技術の世界的リーダーであるオムニポッドブランドの製品タイプInsulet Corporationは、英国で2歳以上の1型糖尿病患者向けにオムニポッド5自動インスリン送達システム（Omnipod 5）を発売しました。オムニポッド5システムは、シンプルさと先進技術が融合した製品です。オムニポッド5は、CEマークを取得した初のチューブレス・ハイブリッド・クローズドループシステムで、デクスコムG6持続血糖モニタリング（CGM）システムと統合することにより、インスリン送達を自動的に調整し、高血糖や低血糖を防ぐことができます。

さらに、チューブレスインスリンポンプにワイヤレス接続とスマート機能を組み込むことで、ユーザーはデジタルプラットフォームを通じてインスリン送達をモニター・コントロールできるようになります。このレベルの接続性は患者の利便性を向上させる。全体として、チューブレスインスリンポンプの進歩は、ユーザーの利便性を向上させ、さらに採用を増加させる。

例えば、2023年2月14日、EOFlow Co.は、チューブレス、ウェアラブル、使い捨てインスリンポンプEOPatchをUAEで発売しました。UAEでは、全く新しいNarshaアプリを使用して、AndroidおよびiOSスマートフォンから直接EOPatchでインスリン注入を制御・管理することが可能になります。

さらに、糖尿病有病率の増加、FDA承認などの規制承認の増加、チューブレスインスリンポンプの利点に関する認知度の向上、デバイスの技術的進歩が、予測期間にわたって市場を牽引すると予想される要因です。

阻害要因

チューブレスインスリンポンプに関連する合併症やリスク、これらのデバイスの高コストなどの要因が市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • チューブレスインスリンポンプの進歩の増加
    • 抑制要因
      • デバイスの高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • DMI意見

第6章 COVID-19分析

第7章 タイプ別

  • インスリンパッチポンプ
  • 使い捨てリザーバー付き従来型ポンプ

第8章 コンポーネント別

  • インスリンポンプ（ポッド）
  • リモートコントローラー

第9章 用途別

  • 1型糖尿病
  • 2型糖尿病

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Insulet Corporation
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • F. Hoffmann-La Roche Ltd
  • Debiotech SA
  • CeQur Corporation
  • Terumo Corporation
  • Tandem Diabetes Care, Inc.
  • EOFLOW CO., LTD.
  • Medtrum Technologies Inc.
  • Microtec Medical
  • Ascensia Diabetes Care Holdings AG

第14章 付録

目次
Product Code: MD7390

Overview

Tubeless insulin pumps are basically worn as a patch directly on the body and controlled from a wireless handheld device, enabling discreet insulin delivery. The pump does not have a screen and is controlled wirelessly from a touchscreen handheld via Bluetooth. It includes an algorithm placed in a waterproof, closed-loop insulin pump and communicates directly with a continuous glucose monitor for the insulin-releasing process.

Moreover, tubeless insulin pumps can help people with type-1 and type-2 diabetes conveniently to manage their blood sugar levels. These small devices deliver doses of insulin at specific times. The tubeless insulin pumps are a more flexible option than insulin pen injections and other insulin devices. These don't have to be permanent and can switch to another insulin management method at any time. Tubeless insulin pumps are favorable to the patients, insulin delivery can be done by using wireless devices.

Market Dynamics: Drivers

Increasing advancements in tubeless insulin pumps

The increasing advancements in tubeless pumps are expected to drive the market over the forecast period. The advancements in these pumps are expected to increase the adoption of tubeless insulin pumps. Advancements in tubeless insulin pump technology may result in devices that are smaller, more comfortable, and easier to use. Improvements in user experience can lead to increased patient satisfaction.

For instance, in August 2023, Roche launched its Accu-Chek Solo insulin patch pump and wireless touchscreen handheld device and it has received FDA approval for people with diabetes aged 2 years and older. The system includes a tubeless insulin pump and a wireless handheld controller with Bluetooth, which integrates with blood glucose monitoring and provides bolus advice. This insulin pump system is tubeless, small and lightweight. The device is detachable, allowing people with diabetes to change the infusion site when necessary.

Moreover, if tubeless insulin pumps are designed to integrate seamlessly with CGM systems, allowing for better glucose monitoring and automated insulin adjustments, it can significantly enhance diabetes management. This results in better patient outcomes and further this increases the adoption of advanced devices.

For instance, on June 20, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, launched its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes in the United Kingdom. The Omnipod 5 System is where simplicity meets advanced technology. Omnipod 5 is the first CE-marked tubeless hybrid closed loop system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin delivery and help protect against high and low glucose levels.

Furthermore, the incorporation of wireless connectivity and smart features of tubeless insulin pumps can empower users to monitor and control their insulin delivery through digital platforms. This level of connectivity can improve patient convenience. Overall, the advancements in tubeless insulin pumps improve user convenience and further increase adoption.

For instance, on February 14, 2023, EOFlow Co. launched its tubeless, wearable, and disposable insulin pump EOPatch in the UAE. It becomes possible in the UAE to control and manage insulin infusions with EOPatch directly from Android and iOS smartphones using the brand-new Narsha app.

In addition, the increasing prevalence of diabetes, rising regulatory approvals such as FDA approvals, increasing awareness about the advantages of tubeless insulin pumps and technological advancements in the devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and risks associated with tubeless insulin pumps and the high cost of these devices are expected to hamper the market.

Segment Analysis

The global tubeless insulin pumps market is segmented based on type, component, application, distribution channel and region.

The insulin patch pumps segment accounted for approximately 43.2% of the tubeless insulin pumps market share

The insulin patch pumps segment is expected to hold the largest market share over the forecast period. Insulin patch pumps are a type of wearable insulin delivery device that adheres to the skin, typically in the form of a patch. These pumps are designed to provide a continuous delivery of insulin. They offer advantages such as discreetness, ease of use, and reduced interference with daily activities.

Moreover, insulin patch pumps are usually designed to adhere securely to the skin, allowing users to wear them for an extended period without discomfort. For instance, on November 16, 2022, Dexcom U.K. launched a campaign led by four local celebrities who designed their own continuous glucose monitor (CGM) insulin patch pumps to tell their Diabetes Story.

Due to the rising prevalence of diabetes, there is a continuously increasing demand for the use of tubeless insulin pumps. For instance, according to the Centers for Disease Control and Prevention, 2022, there are a total of 37.3 million people have diabetes. These insulin patch pumps are often compact and discreet, making them less noticeable and more convenient for users.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing advancements. North America especially the United States is home to the presence of major players such as medical device companies, which are primarily focussing on the development of tubeless insulin pumps by offering more advanced features to increase patient convenience.

For instance, on April 25, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, released the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. With its tubeless and waterproof pod, the Omnipod GO provides an alternative to traditional insulin delivery methods.

Furthermore, increasing advancements for tubeless insulin pumps in the region are also expected to drive the market in the region. For instance, on August 11, 2022, EOFlow officially launched its tubeless, wearable, and disposable insulin pump under the diabetes care brand GlucoMen Day PUMP. These advancements increase the adoption of tubeless insulin pumps in the region.

Competitive Landscape

The major global players in the tubeless insulin pumps market include: Insulet Corporation, F. Hoffmann-La Roche Ltd, Debiotech SA, CeQur Corporation, Terumo Corporation, Tandem Diabetes Care, Inc., EOFLOW CO., LTD., Medtrum Technologies Inc., Microtec Medical and Ascensia Diabetes Care Holdings AG among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global tubeless insulin pumps market. During the pandemic, the demand for the tubeless insulin pumps has increased. For instance, according to NIH 2020, obesity and diabetes are two major risk factors for COVID-19 hospitalization. The organization stated that people with diabetes mellitus and severe obesity are more likely to get infected and are at a higher risk of mortality from COVID-19. Among elderly patients who are at higher risk of death from COVID-19, 26.8% have diabetes mellitus, this increased the demand for the adoption of tubeless insulin pumps. However, the pandemic also disrupted the supply chain of these devices globally.

Market Segmentation

By Type

  • Insulin Patch Pumps
  • Traditional Pumps with Disposable Reservoirs

By Component

  • Insulin Pump (Pod)
  • Remote Controller

By Application

  • Type-1 Diabetes
  • Type-2 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global tubeless insulin pumps market segmentation based on type, component, application, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of tubeless insulin pumps market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global tubeless insulin pumps market report would provide approximately 69 tables, 64 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Component
  • 3.3. Snippet by Application
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Advancements in Tubeless Insulin Pumps
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Insulin Patch Pumps*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Traditional Pumps with Disposable Reservoirs

8. By Component

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 8.1.2. Market Attractiveness Index, By Component
  • 8.2. Insulin Pump (Pod)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Remote Controller

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Type-1 Diabetes*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Type-2 Diabetes

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Insulet Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. F. Hoffmann-La Roche Ltd
  • 13.3. Debiotech SA
  • 13.4. CeQur Corporation
  • 13.5. Terumo Corporation
  • 13.6. Tandem Diabetes Care, Inc.
  • 13.7. EOFLOW CO., LTD.
  • 13.8. Medtrum Technologies Inc.
  • 13.9. Microtec Medical
  • 13.10. Ascensia Diabetes Care Holdings AG

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us